Page last updated: 2024-11-11

codeine-6-glucuronide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

codeine-6-glucuronide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5489029
CHEBI ID80580
SCHEMBL ID6753388
MeSH IDM0171197

Synonyms (25)

Synonym
codeine-6-glucuronide
C16577 ,
20736-11-2
e2m937ky47 ,
unii-e2m937ky47
beta-d-glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-yl
beta-d-galactopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-yl
219533-59-2
.beta.-d-glucopyranosiduronic acid, (5.alpha.,6.alpha.)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-yl
CHEBI:80580
SCHEMBL6753388
codeine 6-beta-d-glucuronide 0.1 mg/ml in water
codeine 6-beta-d-glucuronide
codeine 6-beta-d-glucuronide 1.0 mg/ml in water
bdbm224022
codeine-6g
morphinan, 7,8-didehydro-4,5a-epoxy-6a-(b-d-glucopyranuronosyloxy)-3-methoxy-17-methyl- (8ci)
glucopyranosiduronic acid, codeine, b-d- (6ci)
glucopyranosiduronicacid, 7,8-didehydro-4,5a-epoxy-3-methoxy-17-methylmorphinan-6a-yl, b-d- (8ci)
codeine glucuronide
c-6-g hydrate-trifluoroacetate
Q5140137
(2s,3s,4s,5r,6r)-6-[[(4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DTXSID60942952
codeine-6-ss-d-glucuronide-d3 solution

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" We aimed to develop a codeine pharmacokinetic pathway model for codeine and its metabolites that incorporates the effects of genetic polymorphisms."( CYP2D6 phenotype-specific codeine population pharmacokinetics.
Boston, RC; Daly Linares, AL; Fudin, J; Linares, OA; Schiesser, WE, 2015
)
0.42
"The purpose of this study was to determine the pharmacokinetic and antinociceptive effects of an acetaminophen/codeine combination administered orally to six healthy greyhounds."( Pharmacokinetics and pharmacodynamics of oral acetaminophen in combination with codeine in healthy Greyhound dogs.
KuKanich, B, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" Thus, in vitro-in vivo extrapolation approaches were used to identify potential drug-drug interactions arising from inhibition of COD glucuronidation in humans."( In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans.
Elliot, DJ; Janchawee, B; Miners, JO; Raungrut, P; Somogyi, AA; Uchaipichat, V, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Our study suggests that pharmacogenetics for personalized dosing might be most effectively advanced by studying the interplay between pharmacogenetics, population pharmacokinetics, and clinical pharmacokinetics."( CYP2D6 phenotype-specific codeine population pharmacokinetics.
Boston, RC; Daly Linares, AL; Fudin, J; Linares, OA; Schiesser, WE, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
morphinane alkaloidAn isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Codeine Action Pathway3420
Codeine Metabolism Pathway411
Codeine and Morphine Pathway, Pharmacokinetics165
Codeine and morphine metabolism07

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mas-related G-protein coupled receptor member X2Homo sapiens (human)EC50 (µMol)44.00000.14003.73818.9000AID1802709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
sensory perception of painMas-related G-protein coupled receptor member X2Homo sapiens (human)
sleepMas-related G-protein coupled receptor member X2Homo sapiens (human)
positive regulation of cytokinesisMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell degranulationMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell activationMas-related G-protein coupled receptor member X2Homo sapiens (human)
G protein-coupled receptor signaling pathwayMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityMas-related G-protein coupled receptor member X2Homo sapiens (human)
neuropeptide bindingMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell secretagogue receptor activityMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
membraneMas-related G-protein coupled receptor member X2Homo sapiens (human)
plasma membraneMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1802709PRESTO-Tango Assay from Article 10.1038/nchembio.2334: \\In silico design of novel probes for the atypical opioid receptor MRGPRX2.\\2017Nature chemical biology, 05, Volume: 13, Issue:5
In silico design of novel probes for the atypical opioid receptor MRGPRX2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.23)18.7374
1990's7 (22.58)18.2507
2000's9 (29.03)29.6817
2010's13 (41.94)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.02 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index5.40 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (17.65%)5.53%
Reviews2 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (76.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]